Scientists test new drug switch strategy for multiple sclerosis
NCT ID NCT04178005
Summary
This study aims to understand the safety and effects of switching patients with relapsing forms of multiple sclerosis (MS) from the medication natalizumab to a different pill called cladribine tablets. It will follow 40 adults for two years to see how their immune cells and disease activity change after the switch. The goal is to gather information to help doctors better manage MS treatment transitions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
College Park Family Care Center Physicians Group
Overland Park, Kansas, 66212, United States
-
UT Southwestern Medical center
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.